HC Wainwright Forecasts Genmab A/S FY2024 Earnings

Genmab A/S (NASDAQ:GMAB) – Equities researchers at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Genmab A/S in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $1.21 per share for the year. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.35 EPS.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period last year, the business posted $0.47 EPS.

A number of other brokerages have also issued reports on GMAB. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Price Performance

NASDAQ GMAB opened at $19.58 on Monday. Genmab A/S has a 12 month low of $19.02 and a 12 month high of $31.88. The company has a market capitalization of $12.96 billion, a price-to-earnings ratio of 19.01, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. The firm’s fifty day moving average price is $21.09 and its 200 day moving average price is $23.87.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in GMAB. Two Sigma Advisers LP boosted its position in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the period. Sanctuary Advisors LLC bought a new stake in Genmab A/S during the second quarter worth approximately $1,354,000. Natixis Advisors LLC lifted its position in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after purchasing an additional 47,437 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after purchasing an additional 34,652 shares in the last quarter. Finally, FMR LLC increased its position in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after purchasing an additional 33,076 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.